April 1, 2016
Gilead Sciences said on March 31 that it has filed a new drug application (NDA) in Japan for tenofovir alafenamide (TAF) 25 mg, a once-daily treatment for adults with chronic hepatitis B virus (HBV) infection with or without cirrhosis. TAF...read more